{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:23:00Z","timestamp":1793499780410,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ajog.2021.04.227","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T17:44:18Z","timestamp":1618854258000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Drug development research in pregnant and lactating women"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-1496","authenticated-orcid":false,"given":"Zhaoxia","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Pawlyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.04.227_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/AOG.0000000000002357","article-title":"Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005-2014","volume":"130","author":"Admon","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib2","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.wombi.2017.12.004","article-title":"Why does the need for medication become a barrier to breastfeeding? A narrative review","volume":"31","author":"McClatchey","year":"2018","journal-title":"Women Birth"},{"key":"10.1016\/j.ajog.2021.04.227_bib4","doi-asserted-by":"crossref","first-page":"690.e1","DOI":"10.1016\/j.ajog.2014.06.013","article-title":"Trends in pregnancy labeling and data quality for US-approved pharmaceuticals","volume":"211","author":"Mazer-Amirshahi","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/1471-0528.14151","article-title":"The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy","volume":"124","author":"Scaffidi","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2021.04.227_bib6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa1013961","article-title":"Adverse health outcomes in women exposed in utero to diethylstilbestrol","volume":"365","author":"Hoover","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJM198702263160905","article-title":"Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update","volume":"316","author":"Melnick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib8","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1001\/jama.1984.03350210027024","article-title":"Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol-exposed Young women. Experience of the national collaborative diethylstilbestrol adenosis project","volume":"252","author":"Robboy","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2021.04.227_bib9","doi-asserted-by":"crossref","first-page":"E233","DOI":"10.1148\/rg.326125515","article-title":"Imaging of M\u00fcllerian duct anomalies","volume":"32","author":"Behr","year":"2012","journal-title":"Radiographics"},{"key":"10.1016\/j.ajog.2021.04.227_bib10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities","volume":"278","author":"McBride","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2021.04.227_bib11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jmg.29.10.716","article-title":"Recognition of thalidomide defects","volume":"29","author":"Smithells","year":"1992","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ajog.2021.04.227_bib12","first-page":"39406","article-title":"Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice","volume":"58","year":"1993","journal-title":"Fed Regist"},{"key":"10.1016\/j.ajog.2021.04.227_bib13","first-page":"103","article-title":"National Institutes of Health revitalization act of 1993. Science and technology","year":"1993","journal-title":"Public Law"},{"key":"10.1016\/j.ajog.2021.04.227_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.31486\/toj.19.0077","article-title":"Research in pregnant subjects: increasingly important, but challenging","volume":"20","author":"Biggio","year":"2020","journal-title":"Ochsner J"},{"key":"10.1016\/j.ajog.2021.04.227_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/sper.2001.24564","article-title":"Introduction: medication use in pregnancy","volume":"25","author":"Giacoia","year":"2001","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/clpt.2009.5","article-title":"Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice","volume":"85","author":"Hebert","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ajog.2021.04.227_bib17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/dmd.109.031245","article-title":"Pharmacokinetics of metformin during pregnancy","volume":"38","author":"Eyal","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib18","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/dmd.108.024984","article-title":"Clonidine pharmacokinetics in pregnancy","volume":"37","author":"Buchanan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/0091270009358708","article-title":"Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum","volume":"50","author":"Eyal","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-014-0133-6","article-title":"Pharmacokinetics of indomethacin in pregnancy","volume":"53","author":"Rytting","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajog.2021.04.227_bib22","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ajog.2011.03.002","article-title":"Pharmacokinetics of oseltamivir among pregnant and nonpregnant women","volume":"204","author":"Beigi","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/13543784.2016.1196185","article-title":"The early developments of preeclampsia drugs","volume":"25","author":"Costantine","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ajog.2021.04.227_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.semperi.2014.08.019","article-title":"Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention","volume":"38","author":"Cleary","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric--Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib26","doi-asserted-by":"crossref","first-page":"373.e1","DOI":"10.1016\/j.ajog.2013.05.038","article-title":"Transplacental transfer and distribution of pravastatin","volume":"209","author":"Nanovskaya","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/bmc.3314","article-title":"Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS\/MS","volume":"29","author":"Zhang","year":"2015","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.ajog.2021.04.227_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/jpet.114.213470","article-title":"Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age","volume":"350","author":"Shuster","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ajog.2021.04.227_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jchromb.2007.10.010","article-title":"Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study","volume":"860","author":"Naraharisetti","year":"2007","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ajog.2021.04.227_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/AOG.0b013e31829007f0","article-title":"A\u00a0pharmacologic approach to the use of glyburide in pregnancy","volume":"121","author":"Caritis","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib31","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/cpt.1749","article-title":"Pharmacodynamics of glyburide, metformin, and glyburide\/metformin combination therapy in the treatment of gestational diabetes mellitus","volume":"107","author":"Shuster","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ajog.2021.04.227_bib32","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1124\/dmd.110.033837","article-title":"Increased glyburide clearance in the pregnant mouse model","volume":"38","author":"Zhou","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/bdd.706","article-title":"Contributions of human cytochrome P450 enzymes to glyburide metabolism","volume":"31","author":"Zhou","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.bcp.2009.08.003","article-title":"Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide","volume":"78","author":"Zharikova","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1061503","article-title":"Glyburide metabolism by placentas of healthy and gestational diabetics","volume":"25","author":"Jain","year":"2008","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib36","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.bcp.2007.03.005","article-title":"Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon","volume":"73","author":"Zharikova","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib37","doi-asserted-by":"crossref","first-page":"383.e1","DOI":"10.1016\/j.ajog.2010.01.035","article-title":"Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin","volume":"202","author":"Hemauer","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14767050801929901","article-title":"Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide","volume":"21","author":"Nanovskaya","year":"2008","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1124\/mol.107.041616","article-title":"The breast cancer resistance protein (Bcrp1\/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study","volume":"73","author":"Zhou","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/dmd.119.088435","article-title":"Effects of pregnancy on the pharmacokinetics of metformin","volume":"48","author":"Liao","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcph.1549","article-title":"Pharmacodynamics of metformin in pregnant women with gestational diabetes mellitus and nonpregnant women with type 2 diabetes mellitus","volume":"60","author":"Shuster","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.semperi.2014.08.015","article-title":"Oseltamivir for influenza in pregnancy","volume":"38","author":"Beigi","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib43","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3109\/14767058.2012.693993","article-title":"Transplacental transfer of oseltamivir carboxylate","volume":"25","author":"Nanovskaya","year":"2012","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib44","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/bcp.12691","article-title":"Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women","volume":"80","author":"Pillai","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.semperi.2014.08.016","article-title":"Pharmacological management of hypertension in pregnancy","volume":"38","author":"Easterling","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib46","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/ajh.2010.159","article-title":"Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth","volume":"23","author":"Rothberger","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ajog.2021.04.227_bib47","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1124\/dmd.110.033878","article-title":"CYP2D6 mediates 4-hydroxylation of clonidine in\u00a0vitro: implication for pregnancy-induced changes in clonidine clearance","volume":"38","author":"Claessens","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib48","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.semperi.2014.08.013","article-title":"Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations","volume":"38","author":"Feghali","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib49","doi-asserted-by":"crossref","first-page":"128.e1","DOI":"10.1016\/j.ajog.2013.10.008","article-title":"Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth","volume":"210","author":"Caritis","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib50","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.ajog.2012.08.015","article-title":"Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation","volume":"207","author":"Caritis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib51","doi-asserted-by":"crossref","first-page":"47.e1","DOI":"10.1016\/j.ajog.2013.09.039","article-title":"Obstetrical-Fetal Pharmacology Research Units Network. Quality assessment of compounded 17-hydroxyprogesterone caproate","volume":"210","author":"Chang","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib52","doi-asserted-by":"crossref","first-page":"470.e1","DOI":"10.1016\/j.ajog.2013.02.028","article-title":"Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate","volume":"208","author":"Caritis","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/dmd.112.044891","article-title":"Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes","volume":"41","author":"Sharma","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/dmd.109.029918","article-title":"Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes","volume":"38","author":"Sharma","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib55","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1124\/dmd.108.021444","article-title":"Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth","volume":"36","author":"Sharma","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib56","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.bcp.2008.01.013","article-title":"Metabolism of 17alpha-hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons","volume":"75","author":"Yan","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1933719111419248","article-title":"Metabolism of 17-alpha-hydroxyprogesterone caproate by human placental mitochondria","volume":"19","author":"Fokina","year":"2012","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajog.2021.04.227_bib58","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jpba.2008.08.024","article-title":"Simultaneous quantitation of 17alpha-hydroxyprogesterone caproate, 17alpha-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS\/MS)","volume":"48","author":"Zhang","year":"2008","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.ajog.2021.04.227_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jchromb.2007.05.028","article-title":"Development and validation of a high-performance liquid chromatography-mass spectrometric assay for the determination of 17alpha-hydroxyprogesterone caproate (17-OHPC) in human plasma","volume":"856","author":"Zhang","year":"2007","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ajog.2021.04.227_bib60","doi-asserted-by":"crossref","first-page":"169.e1","DOI":"10.1016\/j.ajog.2007.11.065","article-title":"Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate","volume":"199","author":"Hemauer","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jpba.2014.04.030","article-title":"Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS","volume":"98","author":"Wang","year":"2014","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.ajog.2021.04.227_bib62","doi-asserted-by":"crossref","first-page":"331.e1","DOI":"10.1016\/j.ajog.2012.06.064","article-title":"Transplacental transfer of vancomycin and telavancin","volume":"207","author":"Nanovskaya","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jpba.2013.02.006","article-title":"A\u00a0liquid chromatography method with single quadrupole mass spectrometry for quantitative determination of indomethacin in maternal plasma and urine of pregnant patients","volume":"78\u201379","author":"Wang","year":"2013","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.ajog.2021.04.227_bib64","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-014-2406-z","article-title":"Pharmacokinetics of doxorubicin in pregnant women","volume":"73","author":"Ryu","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib65","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bcp.12122","article-title":"Tacrolimus placental transfer at delivery and neonatal exposure through breast milk","volume":"76","author":"Zheng","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib66","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","article-title":"Interpreting tacrolimus concentrations during pregnancy and postpartum","volume":"95","author":"Hebert","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.ajog.2021.04.227_bib67","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0b013e3182708edf","article-title":"Pharmacokinetics of tacrolimus during pregnancy","volume":"34","author":"Zheng","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ajog.2021.04.227_bib68","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0890334413479671","article-title":"Duration of cisplatin excretion in breast milk","volume":"29","author":"Hays","year":"2013","journal-title":"J\u00a0Hum Lact"},{"key":"10.1016\/j.ajog.2021.04.227_bib69","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/bmc.2873","article-title":"Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry","volume":"27","author":"Wang","year":"2013","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.ajog.2021.04.227_bib70","first-page":"275","article-title":"Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic","volume":"30","author":"Haas","year":"2013","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib71","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/14767058.2011.583700","article-title":"A\u00a0pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic","volume":"25","author":"Haas","year":"2012","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib72","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/14767058.2010.497573","article-title":"Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis","volume":"24","author":"Wang","year":"2011","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib73","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMc0706410","article-title":"Serotonin syndrome associated with triptan monotherapy","volume":"358","author":"Soldin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib74","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.clpt.6100126","article-title":"Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies","volume":"81","author":"Andrew","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ajog.2021.04.227_bib75","doi-asserted-by":"crossref","first-page":"151229","DOI":"10.1016\/j.semperi.2020.151229","article-title":"A\u00a0common clinical conundrum: antidepressant treatment of depression in pregnant women","volume":"44","author":"Mesches","year":"2020","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jcph.1122","article-title":"Prednisone pharmacokinetics During pregnancy and lactation","volume":"58","author":"Ryu","year":"2018","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-017-3511-6","article-title":"Pharmacokinetics of dacarbazine (DTIC) in pregnancy","volume":"81","author":"Kantrowitz-Gordon","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib78","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM200010193431601","article-title":"A\u00a0comparison of glyburide and insulin in women with gestational diabetes mellitus","volume":"343","author":"Langer","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib79","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/AOG.0000000000002501","article-title":"ACOG Practice Bulletin No. 190: gestational diabetes mellitus","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bcp.13438","article-title":"Inclusion of pregnant and breastfeeding women in research\u2014efforts and initiatives","volume":"84","author":"Illamola","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib81","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.semperi.2014.08.011","article-title":"Basic obstetric pharmacology","volume":"38","author":"Zhao","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.04.227_bib82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2014.00065","article-title":"Physiologic and pharmacokinetic changes in pregnancy","volume":"5","author":"Costantine","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajog.2021.04.227_bib83","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","article-title":"Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?","volume":"41","author":"Isoherranen","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib84","doi-asserted-by":"crossref","unstructured":"Giacoia G, Mattison D. Glob. libr. women's med., (ISSN: 1756-2228) 2009. https:\/\/doi.org\/10.3843\/GLOWM.10196.","DOI":"10.3843\/GLOWM.10196"},{"key":"10.1016\/j.ajog.2021.04.227_bib85","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/AOG.0000000000000743","article-title":"Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy","volume":"125","author":"Gonzalez","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib86","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10928-020-09687-z","article-title":"Challenges in conducting clinical research studies in pregnant women","volume":"47","author":"McKiever","year":"2020","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ajog.2021.04.227_bib87","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s40262-017-0538-0","article-title":"Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women","volume":"56","author":"Dallmann","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajog.2021.04.227_bib88","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/dmd.112.050161","article-title":"A\u00a0physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women","volume":"41","author":"Ke","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2021.04.227_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10928-020-09676-2","article-title":"Clinical lactation studies and the role of pharmacokinetic modeling and simulation in predicting drug exposures in breastfed infants","volume":"47","author":"Anderson","year":"2020","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ajog.2021.04.227_bib92","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fimmu.2020.01672","article-title":"Pregnancy, viral infection, and COVID-19","volume":"11","author":"Alberca","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajog.2021.04.227_bib93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.yhbeh.2012.02.023","article-title":"Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis","volume":"62","author":"Robinson","year":"2012","journal-title":"Horm Behav"},{"key":"10.1016\/j.ajog.2021.04.227_bib94","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","article-title":"Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020","volume":"69","author":"Zambrano","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajog.2021.04.227_bib95","doi-asserted-by":"crossref","first-page":"S722","DOI":"10.1016\/j.ajog.2020.12.1204","article-title":"LB02 Maternal and neonatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19): a multistate cohort","volume":"224","author":"Metz","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib97","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2214-109X(20)30484-8","article-title":"Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action","volume":"9","author":"Taylor","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ajog.2021.04.227_bib100","article-title":"COVID-19 vaccine response in pregnant and lactating women: a cohort study","author":"Gray","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.04.227_bib103","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.2021.1865","article-title":"Involving pregnant individuals in clinical research on COVID-19 vaccines","volume":"325","author":"Bianchi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2021.04.227_bib104","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.ejps.2019.105068","article-title":"Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies","volume":"140","author":"Atoyebi","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ajog.2021.04.227_bib106","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3109\/14767058.2015.1038518","article-title":"Placenta-on-a-chip: a novel platform to study the biology of the human placenta","volume":"29","author":"Lee","year":"2016","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.04.227_bib107","article-title":"Placental drug transport-on-a-chip: a microengineered in\u00a0vitro model of transporter-mediated drug efflux in the human placental barrier","volume":"7","author":"Blundell","year":"2018","journal-title":"Adv Healthc Mater"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821004579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821004579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:35:54Z","timestamp":1762079754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821004579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0002937821004579"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.04.227","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug development research in pregnant and lactating women","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.04.227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.02.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.03.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}